読み込み中
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
前日終値
$11.95
+$0.31 · +2.66%
日中の時刻はETです。市場データは遅延する場合があります。
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
日中レンジ
現在 $11.95
52週レンジ
現在 $11.95
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
47
適正価値
センチメント
55
まちまち
リスク
59
やや高いリスク
モメンタム
36
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
日中レンジ
現在 $11.95
52週レンジ
現在 $11.95
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 2.44億 USD | 355万 USD | 15.1万 USD | — | 2010万 USD |
| 売上原価 | 150.9万 USD | — | — | — | — |
| 粗利益 | 2.43億 USD | 355万 USD | 15.1万 USD | — | 2010万 USD |
| 研究開発 | 1.3億 USD | 1.74億 USD | 1.35億 USD | 8726.5万 USD | 5514.3万 USD |
| 販売・一般管理 | 4684.9万 USD | 4075.4万 USD | 3483.4万 USD | 2752.5万 USD | 2133万 USD |
| 営業費用 | 1.72億 USD | 2.14億 USD | 1.7億 USD | 1.15億 USD | 7647.3万 USD |
| 受取利息 | — | — | — | 1000 USD | — |
| 支払利息 | — | — | — | 1000 USD | 4000 USD |
| 減価償却費と償却費 | 150.9万 USD | 122.9万 USD | 81.5万 USD | 67.4万 USD | 37.8万 USD |
| 営業利益 | 7062.3万 USD | −2.11億 USD | −1.7億 USD | −1.15億 USD | −5637.3万 USD |
| 純利益 | 8701.4万 USD | −1.87億 USD | −1.53億 USD | −1.05億 USD | −5874.4万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$20.33
上昇余地（70.13%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI659.61万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM564.88万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF258.45万0.00%954億 USD0.05%$235+0.80%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV189.57万0.01%268.09億 USD0.33%$37.95-0.39%
iShares Biotechnology ETFIBB164.08万0.02%108.2億 USD0.44%$206.49+3.00%
EA Bridgeway Omni Small-Cap Value ETFBSVO127万0.05%23.91億 USD0.45%$28.37-0.64%
Schwab U.S. Small-Cap ETFSCHA121.94万0.01%218.24億 USD0.03%$32.79+0.40%
Vanguard Russell 2000 ETFVTWO117.37万0.01%180億 USD0.06%$112.66+0.50%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFU.S. Small Cap Value Portfolio ETF Class SharesDFSViShares Biotechnology ETFIBBEA Bridgeway Omni Small-Cap Value ETFBSVOSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
